Genomic data is considered to be the key to unlocking so-called “precision medicine”. By 2025, around 500 million human genomes will have been sequenced, but with only a fraction being utilised for drug discovery and precision medicine. Lifebit is one of the key startups to emerge in the space, allowing wider access to global biomedical data for drug discovery.
Rare disease patients are likely to receive an accurate diagnosis up to five times more often when human genetic data is involved in the diagnosis, which is why “Clinico-genomic” databases such as Lifebit's can be so transformative. Privacy issues are regularly raised around genomic data, but Lifebit's patented technology federates it, allowing researchers to get more insights while keeping the data secure.
So far, the company has acquired clients across the public and private sectors, including the Hong Kong Genome Project, and an AI partnership with German pharma giant Boehringer Ingelheim. It also won the UK government contract to power Genomics England. Its already-leading position means that Lifebit will continue to experience rapid global adoption and accelerated breakthroughs in precision medicine.
Steph
Company Specialist at Welcome to the Jungle
